-

06:32:38 PM

EGRX Stock News

EGRX - Eagle Pharmaceuticals Inc

01/10/23 2:00 PM

Nasdaq : EGRX

low float

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per

RHEA-AI

neutral

12/21/22 4:30 PM

Nasdaq : EGRX

conferenceslow float

Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference

RHEA-AI

neutral

12/19/22 6:50 AM

Nasdaq : EGRX

fda approvallow float

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous

RHEA-AI

positive

12/12/22 6:50 AM

Nasdaq : EGRX

low float

Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange Book-listed patents against Accord

RHEA-AI

neutral

12/01/22 6:50 AM

Nasdaq : EGRX

low float

Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline

RHEA-AI

neutral

11/16/22 6:50 AM

Nasdaq : EGRX

low float

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline

RHEA-AI

neutral

11/14/22 6:50 AM

Nasdaq : EGRX

acquisitionlow float

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

CAL02 is being developed as an adjunct to the clinically indicated

RHEA-AI

positive

11/09/22 6:50 AM

Nasdaq : EGRX

low float

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line

RHEA-AI

neutral

11/07/22 6:50 AM

Nasdaq : EGRX

low float

Eagle Pharmaceuticals Reports Third Quarter 2022 Results

Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share

RHEA-AI

neutral

10/31/22 6:50 AM

Nasdaq : EGRX

conferencesearningslow float

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens. Scott Tarriff, President and

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

EGRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.eagleus.com
CeoScott Tarriff
Security nameEagle Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees102
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address50 Tice Blvd Ste 315
StateNew Jersey
CityWoodcliff Lake
Zip07677-7637
CountryUS
Phone12013265300

About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.